Generic Name and Formulations:
Penicillin G potassium 5million Units, 20million Units (IV infusion only); per vial; pwd for IM, IV, intrapleural, intrathecal inj after reconstitution; contains sodium 6.8mg, potassium 65.6mg; per 1million Units.
Indications for PFIZERPEN:
Susceptible severe infections where rapid and high penicillin levels are required (see literature).
Adults and Children:
Bacteremia, pneumonia, endocarditis, pericarditis, empyema, meningitis, other severe infections (due to streptococci, pneumococci, staphylococci): minimum of 5million Units per day. Syphilis: dosage and duration determined by age of patient and stage of disease. Gonorrheal endocarditis: minimum 5million Units per day. Meningococcic meningitis: 1–2million Units IM every 2 hours, or continuous IV drip of 20–30million Units/day. Actinomycosis: 1–6million Units/day for cervicofacial cases; 10–20million Units/day for thoracic and abdominal disease. Clostridial infections: 20million Units/day as adjunctive therapy to antitoxin. Fusospirochetal infections: severe infections of oropharynx, lower respiratory tract, and genital area: 5–10million Units/day. Rat-bite fever: 12–15million Units/day for 3–4 weeks. Listeria infections: Neonates: 500,000–1million Units/day. Adults with meningitis: 15–20million Units/day for 2 weeks. Adults with endocarditis: 15–20million Units/day for 4 weeks. Pasteurella infections: Bacteremia and meningitis: 4–6million Units/day for 2 weeks. Ersipeloid: Endocarditis: 2–20million Units/day for 4–6 weeks. Gram-negative bacillary infections: Bacteremia: 20–80million Units/day. Diphtheria (carrier state): 300,000–400,000 Units/day in divided doses for 10–12 days. Anthrax: a minimum of 5million Units/day in divided doses until cure is effected. See literature re: prophylaxis of bacterial endocarditis in dental procedures.
Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Electrolyte imbalance possible with rapid IV infusion; infuse slowly and monitor electrolytes frequently. Monitor renal, hepatic and hematopoietic function with long-term therapy. Newborns. Infants. Pregnancy (Cat.B). Nursing mothers.
Bacteriostatic antibiotics (eg, erythromycin, tetracycline) may diminish bactericidal effects. Potentiated by probenecid. May cause positive Coombs test.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions.
Vials (5million Units)—10; 20million Units—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|